👀Follow-up: Look deeper, not just at the candle.
I get you - the chart does scream “setup.” But let not miss what’s under the hood
Mainz Biomed isn’t just another biotech dreamer. Their product - ColoAlert - is:
already used in Europe,
showing strong accuracy data,
and could be a real alternative to colonoscopy (we’re talking billion-dollar market).
Yeah, #FDA is a tough game. They didn’t get the breakthrough designation last time - but now they’re playing it smart: launching a real clinical trial, gathering data, expanding partnerships.
And look at the competitors:
$EXAS - huge but slow-moving. Cologuard is great, but pricey.
$GH - pushing Shield, but still working to get into frontline screening.
Meanwhile, $MYNZ is going simple and smart: sell ColoAlert as an “easy at-home solution” before symptoms even appear. That disruption - if FDA gives the green light
I personally added on the dip. This isn’t about next week - it about being in before the approval.
$INTC $BAC $AMZN $AMC $GME $HOLO
$MYNZ: Random pump or a textbook setup?
Before yesterday breakout, the stock was lying flat like a forgotten coin under the couch - low price, weak volume. Then suddenly, +17% out of nowhere?
Looks like a classic "shakeout before the breakout." Weak hands got flushed, market looked quiet, and then on thin volume, the price shot up. Someone clearly knew.
Why does it matter? Mainz Biomed:
launched eAArly DETECT 2 (trial is live),
is clearing the path for an FDA resubmission,
and could be lining up for major ColoAlert® news.
This doesn’t feel like a random pump. It feels like strategic positioning ahead of a real FDA story - where the upside isn't +17%, it multiples.
Trader opinion: this was a calculated move. Smart, sharp, and likely setting up for a fundamental.
$NIO $NKE $PLTR $NVDA $AAPL $TSLA
$HOLO 🚨 BREAKING: Mainz Biomed enrolls first patient in its 2,000-patient eAArly DETECT 2 trial, aiming to validate a next-gen colorectal cancer test. Using mRNA biomarkers + AI, it targets early detection of precancerous lesions to help prevent CRC. Results expected Q4 2025! 🧬
$AMC $GME $NVDA $TSLA $HPE $PLTR $INTC
$HOLO 🚨 BREAKING: Mainz Biomed enrolls first patient in its 2,000-patient eAArly DETECT 2 trial, aiming to validate a next-gen colorectal cancer test. Using mRNA biomarkers + AI, it targets early detection of precancerous lesions to help prevent CRC. Results expected Q4 2025! 🧬
$AMC $GME $NVDA $TSLA $HPE $PLTR $INTC